Hot Up And Coming Stocks To Own Right Now

Things haven't been going so hot for Taiwanese smartphone OEM HTC lately. Unfortunately for the aspiring turnaround candidate, things are getting worse before they get better.

The company's One smartphone is tasked with driving HTC's turnaround. All other considerations aside, the flagship device looks like quite a contender with its Apple-caliber hardware and revamped software overlay. The tough part thus far has been getting the device in consumers' hands, since HTC component shortages caused the company to delay the One's launch.

STMicroelectronics (NYSE: STM  ) and OmniVision (NASDAQ: OVTI  ) are the two camera suppliers, and HTC is reportedly no longer considered a "tier one" manufacturer so it doesn't get priority any more. That implies that one of these image sensor specialists was giving HTC the cold shoulder in favor of bigger names.

Marketing matters
Samsung has simply buried HTC in a marketing avalanche that HTC can't keep up with, even if HTC's products are higher quality. HTC had vowed to ditch its "Quietly Brilliant" tag line in an effort to shift toward louder marketing. That was nearly a month ago, and that modest motto is still prominently displayed on its site.

Top 10 Income Stocks To Watch For 2015: NMI Holdings Inc (NMIHZ)

NMI Holdings, Inc. (NMIH), incorporated on May 19, 2011, is a development-stage company. The Company through its subsidiaries provides private mortgage insurance in the United States. The Company�� wholly owned subsidiaries include National Mortgage Insurance Corporation and National Mortgage Reinsurance Inc One.

On April 24, 2012, NMI Holdings, Inc. (NMI) closed an agreement with MAC Financial Ltd. to acquire MAC Financial Holdings Corporation and its wholly owned subsidiaries. On September 30, 2013, the Company merged MAC Financial Holding Corporation into NMIH, with NMIH surviving the merger, and it merged NMRI Two into NMIC, with NMIC surviving the merger.

Advisors' Opinion:

• [By Zachary Tracer]

  NMI Holdings Inc. (NMIHZ), a mortgage insurer backed by funds tied to Carlyle Group LP (CG) and Kyle Bass, filed to sell shares in an initial public offering as investors bet on a housing-market rebound.

Hot Up And Coming Stocks To Own Right Now: Franklin Universal Trust (FT)

Franklin Universal Trust (the Fund) is a diversified, closed-end investment company. The Fund�� primary investment objective is to provide high current income consistent with preservation of capital. Its secondary objective is growth of income through dividend increases and capital appreciation. The Fund invests primarily in two asset classes: high-yield bonds and utility stocks.

The Fund invests in sectors, such as non-energy minerals, utilities, commercial services, communications, consumer durables, consumer non-durables, electronic technology, industrial services, process industries, technology services and transportation. The Fund may invest in the Franklin Institutional Fiduciary Trust Money Market Portfolio (the Sweep Money Fund), an open-end investment company managed by its investment manager. The Fund may invest in restricted securities. The Fund�� investment manager is Franklin Advisers Inc. Its administrative manager is Franklin Templeton Services, LLC.

Advisors' Opinion:

• [By Canadian Value]

  (FT): Russia's central bank has warned that Russia's consumer lending sector threatens the country's "financial stability", the same day that it revoked the licence of Master Bank, a midsized retail lender.

• [By Canadian Value]

  (FT): A 500-tonne gap in China's gold consumption data is fueling talk that the central bank took advantage of weak prices last year to bulk up its holdings of the precious metal.

Hot Up And Coming Stocks To Own Right Now: CNA Financial Corp (CNA)

CNA Financial Corporation (CNAF), incorporated in 1967, is an insurance holding company. The Company�� core business commercial property and casualty insurance operations operate in two segments: CNA Specialty and CNA Commercial. Its non-core businesses are managed in two business segments: Life & Group Non-Core and Corporate & Other Non-Core. The Company�� insurance products primarily include commercial property and casualty coverages, including surety. Its services include risk management, information services, and warranty and claims administration. Its products and services are marketed through independent agents, brokers and managing general underwriters to a wide variety of customers, including small, medium and large businesses, associations, professionals and other groups. CNA's property and casualty and remaining life and group insurance operations are primarily conducted by Continental Casualty Company (CCC), The Continental Insurance Company, Western Surety Company and Continental Assurance Company (CAC). On June 10, 2011, CNA completed the acquisition of CNA Surety Corporation. In July 2012, the Company acquired Hardy Underwriting Bermuda Ltd. On December 14, 2012, the Company sold SUR Insurance Agency, Inc. and The Bond Exchange to California Contractors Insurance Services.

CNA Specialty

CNA Specialty provides professional and management liability and other coverages through property and casualty products and services, both domestically and abroad, through a network of brokers, independent agencies and managing general underwriters. CNA Specialty provides solutions for managing the risks of its clients, including architects, lawyers, accountants, health care professionals, financial intermediaries and public and private companies. Product offerings also include surety and fidelity bonds and warranty services.

CNA Specialty includes four business groups: Professional & Management Liability, International, Surety, and Warranty and Alternative Risks! . Professional & Management Liability provides management and professional liability insurance and risk management services and other specialized property and casualty coverages in the United States. This group provides professional liability coverages to various professional firms, including architects, real estate agents, small and mid-sized accounting firms, law firms and technology firms. Professional & Management Liability also provides D&O, employment practices, fiduciary and fidelity coverages. Products within Professional & Management Liability are distributed through brokers, agents and managing general underwriters. Professional & Management Liability, through CNA HealthPro, also offers insurance products to serve the healthcare delivery system. Products include professional liability and associated standard property and casualty coverages, and are distributed on a national basis through brokers, agents and managing general underwriters. Customer segments include long term care facilities, allied health care providers, life sciences, dental professionals and mid-size and large health care facilities.

International provides similar management and professional liability insurance and other specialized property and casualty coverages in Canada and Europe. Surety consists primarily of CNA Surety Corporation (CNA Surety) and its insurance subsidiaries and offers small, medium and large contract and commercial surety bonds. CNA Surety provides surety and fidelity bonds in all 50 states through a combined network of independent agencies.

Warranty and Alternative Risks provides extended service contracts and related products that provide protection from the financial burden associated with mechanical breakdown and other related losses, primarily for vehicles and portable electronic communication devices. These products are distributed through and administered by a wholly owned subsidiary, CNA National Warranty Corporation, or through third party administrators.

! CNA Comme! rcial

CNA Commercial works with an independent agency distribution system and a network of brokers to market a range of property and casualty insurance products and services to small, middle-market and large businesses and organizations domestically and abroad. Products include standard and excess property coverages, as well as marine coverage, and boiler and machinery. Casualty products include standard casualty insurance products such as workers��compensation, general and product liability, commercial auto and umbrella coverages. It also offers pecialized loss-sensitive insurance programs to those customers viewed as higher risk and less predictable in exposure.

The Business insurance group serves smaller commercial accounts and the Commercial insurance group serves middle markets and larger risks. In addition, CNA Commercial provides total risk management services relating to claim and information services to the insurance marketplace, through a wholly owned subsidiary, CNA ClaimPlus, Inc., a third party administrator. The International insurance group primarily consists of the commercial product lines of its operations in Europe, Canada, as well as Hawaii.

CNA Select Risk (Select Risk) includes excess and surplus lines coverages. Risk provides specialized insurance for selected commercial risks on both an individual customer and program basis. Select Risk�� products are distributed throughout the United States through specialist producers, program agents and brokers.

Life & Group Non-Core

The Life & Group Non-Core segment includes the results of the life and group lines of business that are in run-off. It retains block of group reinsurance and life settlement contracts.

Corporate & Other Non-Core

Corporate & Other Non-Core primarily includes certain corporate expenses. This also includes interest on corporate debt, and the results of certain property and casualty business in run-off, including CNA Re and ! A&EP.

Advisors' Opinion:

• [By Tom Stoukas]

  Centrica Plc (CNA), the largest energy supplier to U.K. homes, lost 2.3 percent to 366.9 pence. JPMorgan Chase & Co. downgraded the shares to neutral from overweight, citing proposals from Britain�� Labour Party to freeze energy bills and break up the country�� six biggest power suppliers.

Hot Up And Coming Stocks To Own Right Now: Neuroderm Ltd (NDRM)

Neuroderm Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development of treatments for central nervous system (CNS) disorders. The Company develops liquid levodopa (LD), which is a treatment for Parkinson�� disease (PD). The Company designs product candidates that address needs in the field of Parkinson�� disease and cognition. The Company�� product pipelines includes ND0612L for moderate PD, ND0612H for severe PD, ND0680 for severe PD, ND0701 for severe PD and ND0801for Cognitive Disorders. The Company developed a liquid formulation of levodopa/carbidopa (LD/CD). The Company through its reformulation technology develops a line of LD/CD product candidates administered through a patch-pump or small belt pump that deliver a continuous, controlled dose of LD/CD to the blood stream. The Company�� LD/CD line of product candidates includes ND0612L, ND0612H and ND0680. The Company also develops ND0701, a formulation of continuous apomorphine therapy for the treatment of Parkinson�� disease.

ND0612L for moderate Parkinson�� disease

ND0612L is under development for the treatment of moderate Parkinson�� disease patients who can no longer effectively control their motor complications with oral levodopa. ND0612L is developed as a fixed dose liquid formulation of levodopa and carbidopa to be administered subcutaneously, over a day and night period. The product ND0612L has two versions under development: ND0612L belt pump version, which is subcutaneously administrated via a small belt-pump, and ND0612L Patch Pump Version, which is a second generation product that is subcutaneously administrated via a patch pump.

The Company has conducted two Phase I studies and a Phase IIa clinical study with N0612L. The clinical studies was a single-dose, 24-hour continuous-administration, randomized, double-blind, placebo-controlled study on eight subjects with moderate Parkinson�� disease. The study results demonstrated that subcutaneous deli! very of ND0612L was safe and tolerable, and achieved steady-state plasma levodopa concentrations of 700-900 nanogram/milliliter. Additionally, administration of ND0612L was shown to significantly reduce fluctuations in plasma levodopa concentrations.

The Company is conducting a Phase II randomized, placebo-controlled, double-blind study of ND0612L on approximately 30 Parkinson�� disease patients suffering from motor complications. The study�� primary endpoints are safety and tolerability, as well as the pharmacokinetic profile of levodopa plasma concentrations.

ND0612H for severe Parkinson�� disease

The Company is developing ND0612H for the treatment of severe-stage Parkinson�� disease patients for whom oral drugs are no longer effective. The ND0612H belt pump (CRONO Twin ND) is a drug pump that delivers levodopa/carbidopa (LD/CD) to treat severe Parkinson�� disease patients. ND0612H provides continuous subcutaneous delivery of an adjustable, high dose, LD/CD formulation to improve motor and non-motor complications in patients refractory to oral LD/CD. ND0612H�� is subcutaneously administrated utilizing a belt-pump allowing patients to receive continuous LD/CD therapy round the clock. The Company is conducting Phase II clinical trials on the product ND0612H for the treatment of severe-stage Parkinson�� disease.

ND0680 for severe Parkinson�� disease

ND0680 is indicated for the treatment of very severe Parkinson�� disease, which requires high doses of LD/CD which cannot be provided via oral delivery or using ND0612L and ND0612H. ND0680 is administered via a tube to the duodenum. ND0680 formulation contains a much higher concentration of LD/CD and is administered with the CRONO ND belt pump via the duodenum. The Company is conducting Phase I clinical trials for the development of ND0680

ND0701 for severe Parkinson�� disease

ND0701 is an apomorphine-based product candidate. ND0701 is desi! gned for ! the treatment of patients with severe Parkinson�� disease and do not respond well to LD/CD. ND0701 is administered via a CRONO ND belt pump or a patch pump (1st and 2nd generation, respectively). The Company is conducting Phase I clinical trials for the development of ND0701 indicated for the treatment of severe Parkinson�� disease.

ND0801 for Cognitive Disorders

ND0801 is under development for the treatment of cognition disorders associated with central nervous system diseases, such as Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder (ADD/ADHD), Alzheimer�� disease, Parkinson�� disease and schizophrenia. ND0801�� is covered by a reformulation and is designed to be a nicotine-based combination drug treatment. ND0801 is administered via a transdermal patch.

The Company is conducting tests on ND0801 for the treatment of ADD/ADHD in two centers in Israel in an open-label, Phase IIa, proof-of-concept dose escalation study on approximately 45 adult patients. The study is designed to demonstrate the safety, tolerability and optimal therapeutic doses of ND0801, and evaluate the cognitive improvement in subjects following treatment with escalating doses of ND0801. Interim results from 30 patients enrolled have demonstrated a dose dependent improvement in attention and cognition following seven days of ND0801 treatment with no observed serious side effects.

Advisors' Opinion:

• [By Johanna Bennett]

  NeuroDerm (NDRM) almost tripled in value to $18.14 during regular market hours after posting clinical trial results for its experimental treatment for Parkinson�� disease.

• [By Johanna Bennett]

  NeuroDerm (NDRM) nearly doubled in value today, rising to $12.25 a share after more than 15 million shares changed hands, after the company reported positive results in a small trial for a treatment for Parkinson�� disease.

Hot Up And Coming Stocks To Own Right Now: Nikon Corp (NINOF)

NIKON CORPORATION is mainly engaged in the manufacture and sale of image and video equipment. The Company operates in four business segments. The Precision Equipment segment offers semiconductor exposure apparatus and liquid crystal (LC) exposure apparatus. The Image segment provides digital single-lens reflex (SLR) cameras, compact digital cameras and interchangeable lens. The Instruments segment offers microscopes, measuring machines and semiconductor inspection equipment. The Others segment provides LC photomask substrates and optical components. As of March 31, 2013, the Company has 87 subsidiaries and 10 associated companies. Advisors' Opinion:

• [By MARKETWATCH]

  LOS ANGELES (MarketWatch) -- Japanese stocks opened lower Thursday, as gains for the yen and losses for Wall Street conspired to drive the Nikkei Stock Average (JP:NIK) down 1.2% to 15,333.35, extending Wednesday's 0.6% loss. The Topix fell 0.7%, with the U.S. dollar (USDJPY) slipping to 102.46 yen, down from around 楼102.80 at the start of the previous session, but off its lows in late Wednesday trade. Electronics firms and other techs helped lead the loss, with Sony Corp. (JP:6758) (SNE) falling 1.4%, Nikon Corp. (JP:7731) (NINOF) off 2.4%, and Alps Electric Co. (JP:6770) 1.8% lower. The Nikkei Asian Review reported Thursday that Japan looked set to post its first trade deficit for electronics goods this year. Shares of Yahoo Japan Corp. (JP:4689) (YAHOF) lost 1.4%, even as Bloomberg reported the firm was offering its stake in market-research firm Macromill Inc. (JP:3730) to U.S. private-equity firm Bain Capital at a premium to its most recent close. Shares of Macromill were untraded. Among gainers, Nippon Telegraph & Telephone Corp. (JP:9432) (NTT) rose 2.1%, following a 1.1% gain for its U.S.-listed shares.

• [By MARKETWATCH]

  LOS ANGELES (MarketWatch) -- With the yen holding on to its gains and investors cautious as earnings season kicks off, Japanese stocks slid lower Friday after closing the previous day with some late-session gains. The Nikkei Stock Average (JP:NIK) fell 0.9% to 14,358.28, with the Topix down 0.8%, as the dollar bought 97.36 yen, little changed from 24 hours earlier. The relatively strong yen weighed on some names with high global exposure, as Sharp Corp. (JP:6753) (SHCAF) lost 1%, Pioneer Corp. (JP:6773) (PNCOF) dropped 1.6%, and Bridgestone Corp. (JP:5108) (BRDCF) fell 1.2%. An outlook cut from Canon Inc. (JP:7751) (CAJ) helped send its shares down 1%, while rival Nikon Corp. (JP:7731) (NINOF) lost 1.8%, though Olympus Corp. (JP:7733) (OCPNF) gained 1%. Telecoms were weak, with Softbank Corp. (JP:9984) (SFTBF) falling 2.5%, KDDI Corp. (JP:9433) (KDDIF) down 1.7%, and NTT DoCoMo Inc. (JP:9437) (NTDMF)

Hot Up And Coming Stocks To Own Right Now: China HGS Real Estate Inc.(HGSH)

China HGS Real Estate Inc., through its subsidiary, Shaanxi Guangsha Investment and Development Group Co., Ltd., engages in the real estate development in the People?s Republic of China. It is involved in the construction and sale of residential apartments, parking lots, and commercial properties. The company develops multi-layer, sub-high-rise, and high-rise apartment buildings, as well as office buildings. China HGS Real Estate Inc. was founded in 1995 and is headquartered in Hanzhong City, the People?s Republic of China.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Top losers in the sector included China HGS Real Estate (NASDAQ: HGSH), off 4.8 percent, and China Life Insurance Co (NYSE: LFC), down 4 percent.

• [By Bryan Murphy]

  While the overall market still seems to be figuring out whether it can move any higher in its current overbought state, a handful of names has already figured out they've got plenty of room to keep advancing now that they've gotten the ball rolling again. Among the best of the best are China Hgs Real Estate Inc. (NASDAQ:HGSH), Arrowhead Research Corp. (NASDAQ:ARWR), and Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA). Here's a closer look at each, and why each has some technical upside on front of it.